Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from NVO

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

3 European Stocks to Buy as the Region Recovers

3 European Stocks to Buy as the Region Recovers

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With the EU and euro area expected to grow steadily over the next two years, investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Shell plc (SHEL) could be beneficial.…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 European Stocks to Buy as the Continent’s Economy Recovers

As Europe navigates a complex landscape of slowing inflation, stable employment, and modest GDP growth, it may be an opportune time for investors to consider investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Novartis (NVS), which are poised to capitalize on the continent’s recovery. Read on….

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

1 Huge New Reason This Diet Drug Stock is a Must-Own

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult population was either overweight or obese. That's a massive market that just opened up for NVO.

inkl

Read news from The Economist, FT, and more,
with one subscription

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Investors Business Daily

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

3 Popular Pharma Stocks Worth Buying Now

3 Popular Pharma Stocks Worth Buying Now

The pharmaceutical industry is set for solid growth due to increased demand for effective treatments for regular and rare diseases, an aging population, and ongoing innovations in pharma technology. Hence, investors could consider buying quality pharmaceutical stocks such as Collegium Pharmaceutical (COLL), Novo Nordisk (NVO), and GSK (GSK). Read on.

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investors Business Daily

4 Pharma Giants Sparking Investor Interest

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Get all your
news in one place.

100’s of premium titles.
One news app.

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Investors Business Daily

IBD Live Q&A And Two Key Stock Lists For Feb. 27, 2024

Welcome to IBD Live! This list of FAQs and useful links will speed your learning curve. Some users have reported the inability to access the IBD Live show page on investors.com from their mobile and tablet devices. Please clear your browser cache and relaunch the browser to resolve this issue.…

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Nordisk To Up Production Capacity As Parent Buys Catalent

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

Investors Business Daily

Dow Jones Futures: Microsoft Leads Huge Wave Of Tech Earnings

The stock market rally is right at highs, but Apple and Microsoft lead a massive earnings wave this coming week, along with the Fed meeting.

3 Pharma Stocks for January 2024 Profits

The pharmaceutical industry is thriving, fueled by steady demand for drugs, cost-efficient alternative discoveries, and rapid technological innovations. Hence, fundamentally strong pharma stocks Novo Nordisk (NVO), Eton Pharmaceuticals (ETON), and Pacira BioSciences (PCRX) might be profitable buys now. Read on….

Investors Business Daily

Dow Jones Futures Fall With Boeing, Apple In Focus; Elon Musk Makes This Tesla Threat

Futures fell slightly after the holiday weekend, with more bad news for Apple and Boeing. Tesla CEO Elon Musk made this threat.

Investors Business Daily

Nvidia, Spotify Lead Five Stocks Near Buy Points

Nvidia and Spotify stock outperformed the market during a tough first week. NVDA could make some noise in the coming week with its CES presentation.

Investors Business Daily

Dow Jones Futures Fall Amid Jobs Report As Fed Doubts Grow; Spot Bitcoin ETFs Loom

The major indexes held up Thursday with bullish action from many leading stocks. The December jobs report and spot Bitcoin ETF approvals loom.

1 2 3 4

People

Dipanjan BanchurSince

Kritika SarmahHer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,685 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play